EDiP: the Epitope Dilution Phenomenon. Lessons learnt from a malaria vaccine antigen and its applicability to polymorphic antigens

References

• Remarque EJ, Faber BW, Kocken CH, et al. Apical membrane antigen 1: a malaria vaccine candidate in review. Trends Parasitol. 2008;24:74–84. [Research Support, Non-U.S. Gov’t Review].
   PubMed Web of Science ®Google Scholar
• Narum DL, Thomas AW. Differential localization of full-length and processed forms of PF83/AMA-1 an apical membrane antigen of Plasmodium falciparum merozoites. Mol Biochem Parasitol. 1994;67: 59–68. [0166-6851(94)90096-5 pii].
   PubMed Web of Science ®Google Scholar
• Bannister LH, Hopkins JM, Dluzewski AR, et al. Plasmodium falciparum apical membrane antigen 1 (PfAMA-1) is translocated within micronemes along subpellicular microtubules during merozoite development. J Cell Sci. 2003;116:3825–3834.
   PubMed Web of Science ®Google Scholar
• Howell SA, Withers-Martinez C, Kocken CH, et al. Proteolytic processing and primary structure of Plasmodium falciparum apical membrane antigen-1. J Biol Chem. 2001;276:31311–31320.
   PubMed Web of Science ®Google Scholar
• Kocken CH, Van der Wel AM, Dubbeld MA, et al. Precise timing of expression of a Plasmodium falciparum-derived transgene in Plasmodium berghei is a critical determinant of subsequent subcellular localization. J Biol Chem. 1998;273:15119–15124. [Research Support, Non-U.S. Gov’t].
   PubMed Web of Science ®Google Scholar
• Deans JA, Alderson T, Thomas AW, et al. Rat monoclonal antibodies which inhibit the in vitro multiplication of Plasmodium knowlesi. Clin Exp Immunol. 1982;49:297–309. [Research Support, Non-U.S. Gov’t].
   PubMed Web of Science ®Google Scholar
• Dutta S, Haynes JD, Moch JK, et al. Invasion-inhibitory antibodies inhibit proteolytic processing of apical membrane antigen 1 of Plasmodium falciparum merozoites. Proc Natl Acad Sci U S A. 2003;100:12295–12300. [In Vitro Research Support, U.S. Gov’t, Non-P.H.S.].
   PubMed Web of Science ®Google Scholar
• Dutta S, Haynes JD, Barbosa A, et al. Mode of action of invasion-inhibitory antibodies directed against apical membrane antigen 1 of Plasmodium falciparum. Infect Immun. 2005;73:2116–2122. [Research Support, U.S. Gov’t, Non-P.H.S.].
   PubMed Web of Science ®Google Scholar
• Thomas AW, Deans JA, Mitchell GH, et al. The Fab fragments of monoclonal IgG to a merozoite surface antigen inhibit Plasmodium knowlesi invasion of erythrocytes. MolBiochemParasitol. 1984;13:187–199. [0166-6851(84)90112-9 pii].
   Google Scholar
• Anders RF, Crewther PE, Edwards S, et al. Immunisation with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi. Vaccine. 1998;16:240–247. [S0264-410X(97)88331-4 pii].
   PubMed Web of Science ®Google Scholar
• Hodder AN, Crewther PE, Anders RF. Specificity of the protective antibody response to apical membrane antigen 1. Infect Immun. 2001;69: 3286–3294.
   PubMed Web of Science ®Google Scholar
• Takala SL, Coulibaly D, Thera MA, et al. Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development. Sci Transl Med. 2009;1:2ra5.
   PubMed Web of Science ®Google Scholar
• Faber BW, Abdul KK, Rodriguez-Garcia R, et al. Low levels of polymorphisms and no evidence for diversifying selection on the Plasmodium knowlesi apical membrane antigen 1 gene. PLoS One. 2015;10:e0124400. [PONE-D-14-56179 pii].
   PubMed Web of Science ®Google Scholar
• Pizarro JC, Vulliez-Le Normand B, Chesne-Seck ML, et al. Crystal structure of the malaria vaccine candidate apical membrane antigen 1. Science. 2005;308:408–411. [Research Support, Non-U.S. Gov’t].
   PubMed Web of Science ®Google Scholar
• Chesne-Seck ML, Pizarro JC, Vulliez-Le Normand B, et al. Structural comparison of apical membrane antigen 1 orthologues and paralogues in apicomplexan parasites. Mol Biochem Parasitol. 2005;144:55–67. [Comparative Study Research Support, Non-U.S. Gov’t].
   PubMed Web of Science ®Google Scholar
• Remarque EJ, Faber BW, Kocken CH, et al. A diversity-covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits. Infect Immun. 2008;76:2660–2670. [Research Support, Non-U.S. Gov’t].
   PubMed Web of Science ®Google Scholar
• Genetic distances for AMA1. [cited 30 Nov 2017]. Available from: http://www.bprc.nl/cdn/edip/ama1/
   Google Scholar
• Smith DJ, Lapedes AS, De Jong JC, et al. Mapping the antigenic and genetic evolution of influenza virus. Science. 2004;305:371–376. [1097211 pii].
   PubMed Web of Science ®Google Scholar
• Dutta S, Lee SY, Batchelor AH, et al. Structural basis of antigenic escape of a malaria vaccine candidate. Proc Natl Acad Sci U S A. 2007;104:12488–12493. [Research Support, U.S. Gov’t, Non-P.H.S.].
   PubMed Web of Science ®Google Scholar
• Escalante AA, Lal AA, Ayala FJ. Genetic polymorphism and natural selection in the malaria parasite Plasmodium falciparum. Genetics. 1998;149: 189–202. [Comparative Study Research Support, U.S. Gov’t, Non-P.H.S. Research Support, U.S. Gov’t, P.H.S.].
   PubMed Web of Science ®Google Scholar
• Ord RL, Tami A, Sutherland CJ. ama1 genes of sympatric Plasmodium vivax and P. falciparum from Venezuela differ significantly in genetic diversity and recombination frequency. PLoS One. 2008;3: e3366.
   PubMed Web of Science ®Google Scholar
• Polley SD, Chokejindachai W, Conway DJ. Allele frequency-based analyses robustly map sequence sites under balancing selection in a malaria vaccine candidate antigen. Genetics. 2003;165: 555–561. [Research Support, Non-U.S. Gov’t].
   PubMed Web of Science ®Google Scholar
• Verra F, Hughes AL. Evidence for ancient balanced polymorphism at the apical membrane antigen-1 (AMA-1) locus of Plasmodium falciparum. Mol Biochem Parasitol. 2000;105: 149–153. [S0166-6851(99)00162-0 pii].
   PubMed Web of Science ®Google Scholar
• Thera MA, Doumbo OK, Coulibaly D, et al. A field trial to assess a blood-stage malaria vaccine. N Eng J Med. 2011;365:1004–1013.
   PubMed Web of Science ®Google Scholar
• Remarque EJ, Roestenberg M, Younis S, et al. Humoral immune responses to a single allele PfAMA1 vaccine in healthy malaria-naive adults. PLoS One. 2012;7:e38898. [Clinical Trial Research Support, Non-U.S. Gov’t].
   PubMed Web of Science ®Google Scholar
• Kennedy MC, Wang J, Zhang Y, et al. In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect Immun. 2002;70:6948–6960.
   PubMed Web of Science ®Google Scholar
• Kocken CH, Withers-Martinez C, Dubbeld MA, et al. High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion. Infect Immun. 2002;70:4471–4476. [Research Support, Non-U.S. Gov’t].
   PubMed Web of Science ®Google Scholar
• Kusi KA, Faber BW, Riasat V, et al. Generation of humoral immune responses to multi-allele PfAMA1 vaccines; effect of adjuvant and number of component alleles on the breadth of response. PLoS One. 2010;5:e15391. [Research Support, Non-U.S. Gov’t].
   PubMed Web of Science ®Google Scholar
• Kusi KA, Remarque EJ, Riasat V, et al. Safety and immunogenicity of multi-antigen AMA1-based vaccines formulated with CoVaccine HT and Montanide ISA 51 in rhesus macaques. Malar J. 2011;10:182. [Research Support, Non-U.S. Gov’t].
   PubMed Web of Science ®Google Scholar
• Kusi KA, Faber BW, Van der Eijk M, et al. Immunization with different PfAMA1 alleles in sequence induces clonal imprint humoral responses that are similar to responses induced by the same alleles as a vaccine cocktail in rabbits. Malar J. 2011;10:40. [Research Support, Non-U.S. Gov’t].
   PubMed Web of Science ®Google Scholar
• Kusi KA, Faber BW, Thomas AW, et al. Humoral immune response to mixed PfAMA1 alleles; multivalent PfAMA1 vaccines induce broad specificity. PLoS One. 2009;4:e8110. [Research Support, Non-U.S. Gov’t].
   PubMed Web of Science ®Google Scholar
• Sirima SB, Durier C, Kara L, et al. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel(R) in European and African adults: a phase 1a/1b, randomized, double-blind multi-centre trial. Vaccine. 2017 Sep 22. PubMed PMID: 28947345. DOI:10.1016/j.vaccine.2017.09.027.
   PubMedGoogle Scholar
• Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine with GLA-SE and Alhydrogel ® as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults (AMA1-DiCo). [cited 30 Nov 2017]. Available from: https://clinicaltrials.gov/ct2/show/NCT02014727/
   Google Scholar
• Dutta S, Dlugosz LS, Drew DR, et al. Overcoming antigenic diversity by enhancing the immunogenicity of conserved epitopes on the malaria vaccine candidate apical membrane antigen-1. PLoS Pathog. 2013;9:e1003840.
   PubMed Web of Science ®Google Scholar
• Faber BW, Younis S, Remarque EJ, et al. Diversity covering AMA1-MSP119 fusion proteins as malaria vaccines. Infect Immun. 2013;81:1479–1490. [Research Support, Non-U.S. Gov’t].
   PubMed Web of Science ®Google Scholar
• Miura K, Herrera R, Diouf A, et al. Overcoming allelic specificity by immunization with five allelic forms of Plasmodium falciparum apical membrane antigen 1. Infect Immun. 2013;81:1491–1501. [Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov’t].
   PubMed Web of Science ®Google Scholar
• Kusi KA, Dodoo D, Bosomprah S, et al. Measurement of the plasma levels of antibodies against the polymorphic vaccine candidate apical membrane antigen 1 in a malaria-exposed population. BMC Infect Dis. 2012;12:32. [Research Support, Non-U.S. Gov’t].
   PubMed Web of Science ®Google Scholar
• Osier FH, Fegan G, Polley SD, et al. Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect Immun. 2008;76:2240–2248. [Research Support, Non-U.S. Gov’t Validation Studies].
   PubMed Web of Science ®Google Scholar
• Daou M, Kouriba B, Ouedraogo N, et al. Protection of Malian children from clinical malaria is associated with recognition of multiple antigens. Malar J. 2015;14:56.
   PubMed Web of Science ®Google Scholar
• Davenport FM, Hennessy AV. Predetermination by infection and by vaccination of antibody response to influenza virus vaccines. J Exp Med. 1957;106:835–850.
   PubMed Web of Science ®Google Scholar
• Carter DM, Bloom CE, Nascimento EJ, et al. Sequential seasonal H1N1 influenza virus infections protect ferrets against novel 2009 H1N1 influenza. J Virol. 2013;87:1400–1410.
   PubMed Web of Science ®Google Scholar
• Genetic distances for influenza. [cited 30 Nov 2017]. Available from: http://www.bprc.nl/cdn/edip/dengue/
   Google Scholar
• Huber VC, Thomas PG, McCullers JA. A multi-valent vaccine approach that elicits broad immunity within an influenza subtype. Vaccine. 2009;27:1192–1200. [S0264-410X(08)01747-7 pii].
   PubMed Web of Science ®Google Scholar
• Prabakaran M, Leyrer S, He F, et al. Progress toward a universal H5N1 vaccine: a recombinant modified vaccinia virus Ankara-expressing trivalent hemagglutinin vaccine. PLoS One. 2014;9:e107316.
   PubMed Web of Science ®Google Scholar
• Schwartzman LM, Cathcart AL, Pujanauski LM, et al. An intranasal virus-like particle vaccine broadly protects mice from multiple subtypes of influenza A virus. MBio. 2015;6. [mBio.01044-15 pii].
   Web of Science ®Google Scholar
• Zebedee SL, Lamb RA. Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J Virol. 1988;62:2762–2772.
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Jennings GT. Virus-like particles: combining innate and adaptive immunity for effective vaccination. In: Kaufmann SHE, editor. Novel vaccination strategies. Weinheim: Wiley-VCH Verlag; 2004. p. 415–431.
   Google Scholar
• Schiller J, Chackerian B. Why HIV virions have low numbers of envelope spikes: implications for vaccine development. PLoS Pathog. 2014;10:e1004254.
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol. 2010;10: 787–796. [nri2868 pii].
   PubMed Web of Science ®Google Scholar
• Pushko P, Pearce MB, Ahmad A, et al. Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes. Vaccine. 2011;29:5911–5918. [S0264-410X(11)00932-7 pii].
   PubMed Web of Science ®Google Scholar
• EduFluVac. [cited 30 Nov 2017]. Available from: www.edufluvac.eu
   Google Scholar
• Genetic distances for Dengue. [cited 30 Nov 2017]. Available from: http://www.bprc.nl/cdn/edip/fluh1-ha1/
   Google Scholar
• Balakrishnan T, Bela-Ong DB, Toh YX, et al. Dengue virus activates polyreactive, natural IgG B cells after primary and secondary infection. PLoS One. 2011;6:e29430. [PONE-D-11-12462 pii].
   PubMed Web of Science ®Google Scholar
• Sabin AB. Research on dengue during World War II. Am J Trop Med Hyg. 1952;1:30–50.
   PubMedGoogle Scholar
• Anderson KB, Gibbons RV, Cummings DA, et al. A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand. J Infect Dis. 2014;209:360–368. [jit436 pii].
   PubMed Web of Science ®Google Scholar
• Capeding MR, Tran NH, Hadinegoro SR, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014. [S0140-6736(14)61060-6 pii]. DOI:10.1016/S0140-6736(14)61060-6.
   PubMed Web of Science ®Google Scholar
• Halstead SB. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res. 2003;60:421–467.
   PubMed Web of Science ®Google Scholar
• Hadinegoro SR, Arredondo-Garc¡a JL, Capeding MR, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med. 2015;373:1195–1206.
   PubMed Web of Science ®Google Scholar
• Guy B, Lang J, Saville M, et al. Vaccination against dengue: challenges and current developments. Annu Rev Med. 2016;67:387–404.
   PubMed Web of Science ®Google Scholar
• Dejnirattisai W, Wongwiwat W, Supasa S, et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol. 2014. [ni.3058 pii].
   PubMed Web of Science ®Google Scholar
• Doria-Rose NA, Schramm CA, Gorman J, et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature. 2014;509:55–62. [nature13036 pii].
   PubMed Web of Science ®Google Scholar
• Liao HX, Lynch R, Zhou T, et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature. 2013;496:469–476. [nature12053 pii].
   PubMed Web of Science ®Google Scholar
• Gao F, Bonsignori M, Liao HX, et al. Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies. Cell. 2014 Jul 31;158:481–491. Epub 2014 Jul 24. PubMed PMID: 25065977. DOI:10.1016/j.cell.2014.06.022.
   PubMed Web of Science ®Google Scholar
• Sather DN, Carbonetti S, Malherbe DC, et al. Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1. J Virol. 2014 Nov;88:12968–12981. Epub 2014 Aug 13. PubMed PMID: 25122781.
   PubMed Web of Science ®Google Scholar
• Sliepen K, Sanders RW. HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies. Expert Rev Vaccines. 2016;1–17. DOI:10.1586/14760584.2016.1129905.
   Web of Science ®Google Scholar
• Kwong PD, Doyle ML, Casper DJ, et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature. 2002;420:678–682.
   PubMed Web of Science ®Google Scholar
• Jardine J, Julien JP, Menis S, et al. Rational HIV immunogen design to target specific germline B cell receptors. Science. 2013;340:711–716. Epub 2013 Mar 28.
   PubMed Web of Science ®Google Scholar
• Hoot S, McGuire AT, Cohen KW, et al. Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. PLoS Pathog. 2013;9:e1003106. [PPATHOGENS-D-12-02139 pii].
   PubMed Web of Science ®Google Scholar
• Xiao X, Chen W, Feng Y, et al. Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem Biophys Res Commun. 2009;390:404–409. [S0006-291X(09)01817-8 pii].
   PubMed Web of Science ®Google Scholar
• Haynes BF, Kelsoe G, Harrison SC, et al. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study . NatBiotechnol. 2012;30:423–433. [nbt.2197 pii].
   Google Scholar
• Jardine JG, Ota T, Sok D, et al. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. Science. 2015;349:156–161.
   PubMed Web of Science ®Google Scholar
• Dosenovic P, Von Boehmer L, Escolano A, et al. Immunization for HIV-1 broadly neutralizing antibodies in human Ig knockin mice. Cell. 2015;161:1505–1515.
   PubMed Web of Science ®Google Scholar
• Bhiman JN, Anthony C, Doria-Rose NA, et al. Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. Nat Med. 2015;21:1332–1336. [nm.3963 pii].
   PubMed Web of Science ®Google Scholar
• Wang S, Mata-Fink J, Kriegsman B, et al. Manipulating the selection forces during affinity maturation to generate cross-reactive HIV antibodies. Cell. 2015;160:785–797. [S0092-8674(15)00070-7 pii].
   PubMed Web of Science ®Google Scholar
• Sanders RW, Van Gils MJ, Derking R, et al. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science. 2015;349:aac4223.
   Web of Science ®Google Scholar
• Escolano A, Steichen JM, Dosenovic P, et al. Sequential immunization elicits broadly neutralizing anti-HIV-1 antibodies in Ig knockin mice. Cell. 2016 Sep 8;166:1445–1458.e12. PubMed PMID: 27610569.
   PubMed Web of Science ®Google Scholar
• Scarselli M, Arico B, Brunelli B, et al. Rational design of a meningococcal antigen inducing broad protective immunity. Sci Transl Med. 2011;3:91ra62. [3/91/91ra62 pii].
   PubMed Web of Science ®Google Scholar
• Angeletti D, Gibbs JS, Angel M, et al. Defining B cell immunodominance to viruses. Nat Immunol. 2017 Feb 13. PubMed PMID: 28192417. DOI:10.1038/ni.3680.
   PubMed Web of Science ®Google Scholar
• Thrane S, Janitzek CM, Agerbaek MO, et al. A novel virus-like particle based vaccine platform displaying the placental malaria antigen VAR2CSA. PLoSOne. 2015;10:e0143071. [PONE-D-15-32548 pii].
   PubMed Web of Science ®Google Scholar
• Brune KD, Leneghan DB, Brian IJ, et al. Plug-and-display: decoration of virus-like particles via isopeptide bonds for modular immunization. Sci Rep. 2016;6:19234. [srep19234 pii].
   PubMed Web of Science ®Google Scholar
• Kanekiyo M, Wei CJ, Yassine HM, et al. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature. 2013. [nature12202 pii]. DOI:10.1038/nature12202.
   PubMed Web of Science ®Google Scholar
• Walsh SR, Moodie Z, Fiore-Gartland AJ, et al. Vaccination with heterologous HIV-1 envelope sequences and heterologous adenovirus vectors increases T-cell responses to conserved regions: HVTN 083. J Infect Dis. 2016;213:541–550. [jiv496 pii].
   PubMed Web of Science ®Google Scholar